Advances In™ Personalizing MS Management Plans: Strategies for Optimizing Long-Term Patient Outcomes in MS and Individualizing Treatment within the S1P Receptor Modulator Class

Released On
June 7, 2022

Expires On
June 7, 2023

Media Type
Internet

Completion Time
60 minutes

Specialty
Neurology

Topic(s)
Multiple Sclerosis, New Drugs

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

 

This activity is supported by an educational grant from Bristol Myers Squibb.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hours

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward neurologists and other health care providers who care for patients with MS.

Program Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of multiple sclerosis (MS) with a forward-looking perspective on how new and novel agents might impact clinical practice. The integration of biomarkers into diagnosis, efficacy of various disease-modifying therapies with a focus on the sphingosine-1-phosphate receptor modulator (S1PRM) class, and patient-focused risk assessment are presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Assess the role of potential biomarkers and other key indicators of multiple sclerosis (MS) related to early diagnosis of MS
  • Evaluate the disease-modifying drug class of sphingosine 1-phosphate (S1P) receptor modulators for patients with MS regarding recent efficacy and safety data
  • Discuss strategies to individualize management to optimize outcomes for patients with MS

Faculty

FACULTY_NAME

Darin T. Okuda, MD, FAAN, FANA

Professor of Neurology
Director, Neuroinnovation Program
Director, Multiple Sclerosis and Neuroimmunology Imaging Program
Director, Radiologically Isolated Syndrome Consortium
Department of Neurology
UT Southwestern Medical Center
Dallas, TX

FACULTY_NAME

Le H. Hua, MD, FAAN

Director – MS Division
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, NV
Department of Neurology
Assistant Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, OH

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Darin T. Okuda, MD, FAAN, FANA
  • Grant/Research Support: Biogen, EMD Serono, Merck & Co.
Le H. Hua, MD, FAAN
  • Grant/Research Support: Biogen
  • Consultant: Genzyme, Novartis, Genentech, Bristol Myers Squibb, EMD Serono, TG Therapeutics, Horizon, Alexion, Greenwich Biosciences
  • Speaker’s Bureau: Genzyme, Bristol Myers Squibb

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.